Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses:
Research and development	$ 17,031,474	$ 12,955,879
General and administrative (including $517,000 and $447,000 of related party legal expenses, respectively)	10,185,537	12,804,493
Total operating expenses	27,217,011	25,760,372
Loss from operations	(27,217,011)	(25,760,372)
Other income (expense):
Change in fair value of warrant liability	(3,915,393)	3,644,601
Gain on warrant exchange	2,228,697
Interest income	22,077	229,458
Interest expense	(97,133)	(114,243)
Total other income (expenses)	(1,761,752)	3,759,816
Loss before income taxes	(28,978,763)	(22,000,556)
Net loss	$ (28,978,763)	$ (22,000,556)
Basic and diluted loss per common share	$ (0.22)	$ (0.19)
Basic and diluted weighted average shares outstanding	134,250,722	114,533,102